iVeena has been awarded a $150K 2017 USTAR Technology Acceleration Grant to advance development of IVMED-70, our innovative Glaucoma MIGS (Minimally Invasive Glaucoma Stent) device.

Glaucoma affects approximately three million individuals in the US and can lead to blindness if not treated. The current standard of care is to administer eye drops on a daily basis that results in a high level of patient non-compliance and the resulting series side effects. The first MIGS device to eliminate the need for eye drops was recently approved. iVeena has developed what we consider is an improved product (increased aqueous outflow) compared to the currently marked products. “The USTAR TAP grant will allow iVeena to accelerate its pre-clinical development of this product and improve our chances of moving forward to clinical studies" said Jerry Simmons, CEO.